A recent Forbes.com headline refers to U.S. prescription drug pricing practices as “Lessons in Obfuscation.” Unlike most products that have clearly defined prices, prescription drugs start with an acquisition cost paid by the pharmacy, which it then inflates and negotiates down with a pharmacy benefit manager. The result: Drug prices that can vary widely from one health plan to another.
MedBen prefers a drug pricing approach with a lot less guesswork, which is why we now offer pharmacy solutions through MedBen Rx. We’ve developed two unique programs with one common purpose: To provide clients with reduced drug costs and complete transparency.
MedBen Rx Advocate turns the standard list-price negotiation scenario around by using the average actual cost that the pharmacist pays for a drug and adding a reasonable dispensing fee. The pricing starts low and stays there.
MedBen Rx Alliance uses hospital purchasing power to offer substantially lower drug pricing for qualified employers through local pharmacies. It’s a community partnership in which every participant benefits.
The article also states that, in regard to drug rebates, “what amount ultimately [gets] passed through to the end-user remains a carefully guarded trade secret.” But again, that’s not the case with MedBen Rx: 100% of paid rebates go back to the client. Total transparency.
Find out more about MedBen Rx pharmacy solutions by visiting MedBenRx.com or by contacting Vice President of Sales & Marketing Brian Fargus at bfargus@medben.com.